These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22504829)

  • 41. The association of blood lipid parameters variability with ischemic stroke in hypertensive patients.
    Huang YQ; Liu L; Liu XC; Lo K; Tang ST; Feng YQ; Zhang B
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1521-1532. PubMed ID: 33810958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.
    Choy E; Ganeshalingam K; Semb AG; Szekanecz Z; Nurmohamed M
    Rheumatology (Oxford); 2014 Dec; 53(12):2143-54. PubMed ID: 24907149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.
    Wijbrandts CA; van Leuven SI; Boom HD; Gerlag DM; Stroes EG; Kastelein JJ; Tak PP
    Ann Rheum Dis; 2009 Aug; 68(8):1316-21. PubMed ID: 18723565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population.
    Liao KP; Cai T; Gainer VS; Cagan A; Murphy SN; Liu C; Churchill S; Shaw SY; Kohane I; Solomon DH; Plenge RM; Karlson EW
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2046-50. PubMed ID: 23925980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritis.
    Davis LA; Whitfield E; Cannon GW; Wolff RK; Johnson DS; Reimold AM; Kerr GS; Richards JS; Mikuls TR; Caplan L
    Rheumatology (Oxford); 2014 Jun; 53(6):1014-21. PubMed ID: 24489016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.
    Kerr G; Aujero M; Richards J; Sayles H; Davis L; Cannon G; Caplan L; Michaud K; Mikuls T
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1619-26. PubMed ID: 24692402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of a pharmacy care management program for veterans with dyslipidemia.
    Smith MC; Boldt AS; Walston CM; Zillich AJ
    Pharmacotherapy; 2013 Jul; 33(7):736-43. PubMed ID: 23625745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.
    Desai RJ; Eddings W; Liao KP; Solomon DH; Kim SC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):457-66. PubMed ID: 25302481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study.
    Sandoo A; van Zanten JJ; Toms TE; Carroll D; Kitas GD
    BMC Musculoskelet Disord; 2012 Jul; 13():127. PubMed ID: 22824166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.
    Schimmel EK; Yazici Y
    Clin Exp Rheumatol; 2009; 27(3):446-51. PubMed ID: 19604437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study.
    Hassan S; Milman U; Feld J; Eder L; Lavi I; Cohen S; Zisman D
    Arthritis Res Ther; 2016 Nov; 18(1):261. PubMed ID: 27832797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dyslipidemia in rheumatoid arthritis: the possible mechanisms.
    Yan J; Yang S; Han L; Ba X; Shen P; Lin W; Li T; Zhang R; Huang Y; Huang Y; Qin K; Wang Y; Tu S; Chen Z
    Front Immunol; 2023; 14():1254753. PubMed ID: 37954591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
    Kristensen LE; Bliddal H; Christensen R; Karlsson JA; Gülfe A; Saxne T; Geborek P
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):173-9. PubMed ID: 23982986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis.
    Tam LS; Tomlinson B; Chu TT; Li TK; Li EK
    Clin Rheumatol; 2007 Sep; 26(9):1495-8. PubMed ID: 17237906
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
    van Sijl AM; Peters MJ; Knol DL; de Vet RH; Sattar N; Dijkmans BA; Smulders YM; Nurmohamed MT
    Semin Arthritis Rheum; 2011 Dec; 41(3):393-400. PubMed ID: 21665247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.